|
SYMPLICITY HTN - 3: Renal artery denervation fails for resistant hypertension |
 |
 |
|
ACC: Despite meeting primary safety endpoints, SYMPLICITY HTN-3 – the pivotal U.S. trial examining renal denervation for treatment-resistant hypertension – has fallen short of its secondary efficacy goals, and failed to reach its primary efficacy endpoint as announced earlier this year by the study's sponsor. The new data was released March 29 as part of ACC.14 in Washington, DC, and simultaneously published in the New England Journal of Medicine (NEJM).
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
